Klotho Neurosciences, Inc. (NASDAQ:KLTO) Short Interest Update

Klotho Neurosciences, Inc. (NASDAQ:KLTO) saw a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 706,392 shares, a decline of 31.7% from the January 29th total of 1,033,627 shares. Based on an average daily volume of 508,114 shares, the days-to-cover ratio is presently 1.4 days. Currently, 1.1% of the company’s stock are sold short. Currently, 1.1% of the company’s stock are sold short. Based on an average daily volume of 508,114 shares, the days-to-cover ratio is presently 1.4 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Brummer Multi Strategy AB bought a new position in shares of Klotho Neurosciences during the 4th quarter worth about $175,000. XTX Topco Ltd grew its stake in shares of Klotho Neurosciences by 101.2% during the 4th quarter. XTX Topco Ltd now owns 160,569 shares of the company’s stock worth $46,000 after acquiring an additional 80,768 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Klotho Neurosciences during the 4th quarter worth approximately $64,000. Renaissance Technologies LLC acquired a new position in shares of Klotho Neurosciences during the 4th quarter worth approximately $126,000. Finally, Geode Capital Management LLC increased its position in shares of Klotho Neurosciences by 51.8% in the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock worth $142,000 after purchasing an additional 167,905 shares during the period. 20.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on KLTO shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Klotho Neurosciences to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Klotho Neurosciences Trading Up 11.2%

KLTO traded up $0.05 during trading on Friday, reaching $0.53. 13,031,440 shares of the company were exchanged, compared to its average volume of 3,286,552. Klotho Neurosciences has a 52 week low of $0.11 and a 52 week high of $3.91. The stock has a market cap of $39.09 million, a P/E ratio of -1.66 and a beta of 10.27. The firm has a 50 day moving average of $0.31 and a 200 day moving average of $0.46.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.